Rusfertide (subcutaneous, hepcidin mimetic) now @US_FDA ✅ based off #VEIRFY study, Ph III (vs Placebo) in phlebotomy dependent polycythemia vera.
- Improved need of phlebotomy.
- Hct control: 76.9% vs 32.9%
- Improved symptoms/fatigue
#MPNsm#HemeTwitter#OncTwitter